BNP Paribas Financial Markets’s Endocyte, Inc. Common Stock ECYT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-2,125
| Closed | -$37.7K | – | 4504 |
|
|
2018
Q3 | $37.7K | Hold |
2,125
| – | – | ﹤0.01% | 3163 |
|
|
2018
Q2 | $29.3K | Buy |
+2,125
| New | +$25.2K | ﹤0.01% | 3337 |
|
|
2017
Q4 | – | Sell |
-74
| Closed | -$104 | – | 4354 |
|
|
2017
Q3 | $104 | Hold |
74
| – | – | ﹤0.01% | 4155 |
|
|
2017
Q2 | $111 | Sell |
74
-66
| -47% | -$142 | ﹤0.01% | 4175 |
|
|
2017
Q1 | $360 | Sell |
140
-1,850
| -93% | -$4.28K | ﹤0.01% | 3901 |
|
|
2016
Q4 | $5.08K | Sell |
1,990
-577
| -22% | -$1.66K | ﹤0.01% | 3704 |
|
|
2016
Q3 | $7.93K | Buy |
2,567
+1,080
| +73% | +$3.37K | ﹤0.01% | 3278 |
|
|
2016
Q2 | $4.77K | Buy |
+1,487
| New | +$5.45K | ﹤0.01% | 3290 |
|
|
2016
Q1 | – | Sell |
-7,006
| Closed | -$28.1K | – | 3354 |
|
|
2015
Q4 | $28.1K | Sell |
7,006
-754
| -10% | -$3.47K | ﹤0.01% | 3156 |
|
|
2015
Q3 | $35.5K | Buy |
7,760
+4,637
| +148% | +$24.3K | ﹤0.01% | 3085 |
|
|
2015
Q2 | $16.2K | Buy |
3,123
+2,263
| +263% | +$13.6K | ﹤0.01% | 3177 |
|
|
2015
Q1 | $5.38K | Buy |
+860
| New | +$4.96K | ﹤0.01% | 3115 |
|
|
2014
Q4 | – | Sell |
-3,040
| Closed | -$18.5K | – | 3662 |
|
|
2014
Q3 | $18.5K | Buy |
+3,040
| New | +$20.8K | ﹤0.01% | 3225 |
|
|
2014
Q1 | – | Sell |
-395
| Closed | -$4.22K | – | 4014 |
|
|
2013
Q4 | $4.22K | Buy |
+395
| New | +$4.36K | ﹤0.01% | 3211 |
|
|
2013
Q3 | – | Sell |
-10,658
| Closed | -$140K | – | 2789 |
|
|
2013
Q2 | $140K | Buy |
+10,658
| New | +$144K | ﹤0.01% | 2462 |
|
Other funds holding ECYT
BNP Paribas Financial Markets's ECYT Position: Q4 2018 in Review
BNP Paribas Financial Markets sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 2,125 shares — an estimated $37.7K sold.
BNP Paribas Financial Markets first reported a position in ECYT in Q2 2013 and held it in 15 quarters. The position peaked at $140K in Q2 2013. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.
- BNP Paribas Financial Markets reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
- BNP Paribas Financial Markets sold 2,125 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $37.7K.
- BNP Paribas Financial Markets first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 15 quarters.
- BNP Paribas Financial Markets's Endocyte, Inc. Common Stock position peaked at $140K in Q2 2013.
- 2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.
Based on BNP Paribas Financial Markets's 13F filing for Q4 2018, filed 12 Feb 2019.